To further improve the EGFR‐TKI management strategy for lung tumors harboring EGFR mutations, we established a combination therapy that includes EGFR‐TKIs and an antivascular endothelial growth factor (VEGF) antibody, bevacizumab, to treat lung cancer tumors harboring EGFR T790M mutations in vivo (Ichihara et al., 2009; Ninomiya et al., 2013). Here, EGFR is linked to lung carcinoma.